Related Experiment Video
Updated: Aug 11, 2026
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Immunological and genetic studies on hereditary angioedema
K Madaliński1, M Chorazykiewicz, K Prokopowicz
1Department of Clinical Immunology, Child Health Center, Warszawa.
Roczniki Akademii Medycznej W Bialymstoku (1995)
|January 1, 1995
Summary
Hereditary angioedema (HAE) patients show C1-inhibitor deficiency. Fibroblast cell lines from HAE patients synthesized significantly reduced C1-inhibitor, but IFN-gamma therapy increased synthesis.
Area of Science:
- Immunology
- Genetics
- Biochemistry
Background:
- Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling.
- C1-inhibitor deficiency is the primary cause of HAE, impacting the complement system.
- Diagnosis and treatment of HAE in Poland over 15 years involved approximately 80 patients.
Purpose of the Study:
- To evaluate diagnostic aspects and treatment responses in Polish HAE patients.
- To investigate the C1-inhibitor synthesis capacity of fibroblasts from HAE patients.
- To explore the potential of interferon-gamma (IFN-gamma) in modulating C1-inhibitor production.
Main Methods:
- Retrospective analysis of diagnostic and treatment data from 17 HAE patients.
- Establishment and characterization of fibroblast cell lines from 5 HAE patients with type I HAE.
- Assessment of C1-inhibitor (C1-INH) antigen and function, and C4 levels.
- In vitro stimulation of fibroblast cell lines with IFN-gamma to evaluate C1-INH synthesis.
Main Results:
- Detailed analysis of 17 HAE patients (14 female, 3 male) revealed key diagnostic indicators and treatment outcomes.
- Fibroblast cell lines from type I HAE patients synthesized only about 20% of normal C1-INH levels.
- IFN-gamma treatment induced an 11 to 20-fold increase in C1-INH synthesis at the pretranslational level.
Conclusions:
- C1-inhibitor deficiency in HAE patients is associated with significantly impaired C1-INH synthesis by fibroblasts.
- IFN-gamma demonstrates potential as a therapeutic agent by upregulating C1-INH production in HAE fibroblasts.
- Further research into IFN-gamma's role could lead to novel therapeutic strategies for hereditary angioedema.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...